ArticleNeurology and therapy2024

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri

Heinz Wiendl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.